EJNMMI Research

Table 2 Interobserver agreement on axillary staging with FDG-PET/CT in supine or prone position

From: [¹⁸F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy

	Axillary staging						Agreement
	Observer 1		Observer 2		Original report		Observers		Kappa	Obs. & report		*Kappa
Supine PET/CT									0.80			0.78
cALN<4	115	75%	107	70%	108	71%	105	69%		99	65%
cALN≥4	38	25%	46	30%	45	29%	36	24%		34	22%
Total	153	100%	153	100%	153	100%	141	92%		133	87%
Prone PET/CT									0.67			0.74
cALN<4	116	76%	96	63%	108	71%	95	62%		93	61%
cALN≥4	37	24%	57	37%	45	29%	36	24%		35	23%
Total	153	100%	153	100%	153	100%	131	86%		128	84%

Data are N, %.*Fleiss kappa. Original report staging at time of treatment including both supine and prone FDG-PET/CT scans
cALN<4 less than four FDG-positive axillary lymph nodes, cALN≥4 more than four FDG-positive axillary lymph nodes

Back to article page